| P50 | author | Charmane I Eastman | Q59697341 |
| P2093 | author name string | Jonathan S Emens | |
| P2860 | cites work | The dim light melatonin onset following fixed and free sleep schedules | Q23913513 |
| | Individual differences in the amount and timing of salivary melatonin secretion | Q23913514 |
| | The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis | Q24549774 |
| | Non-24-Hour Disorder in Blind Individuals Revisited: Variability and the Influence of Environmental Time Cues | Q24617618 |
| | A three pulse phase response curve to three milligrams of melatonin in humans | Q24642414 |
| | Phase angle of entrainment in morning- and evening-types under naturalistic conditions | Q24643489 |
| | Adverse metabolic and cardiovascular consequences of circadian misalignment | Q24656239 |
| | Stability, precision, and near-24-hour period of the human circadian pacemaker | Q28138096 |
| | Circadian phase response curves to light in older and young women and men | Q28218292 |
| | Melatonin receptors step into the light: cloning and classification of subtypes | Q28297734 |
| | Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study | Q28345129 |
| | Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg | Q28382973 |
| | Circadian rhythm phase shifts and endogenous free-running circadian period differ between African-Americans and European-Americans | Q28387633 |
| | Blacks (African Americans) have shorter free-running circadian periods than whites (Caucasian Americans) | Q28389000 |
| | Sex differences in the circadian profiles of melatonin and cortisol in plasma and urine matrices under constant routine conditions | Q28391241 |
| | Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light | Q28391850 |
| | Circadian rhythms of European and African-Americans after a large delay of sleep as in jet lag and night work | Q28393410 |
| | Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance | Q28393796 |
| | Home Circadian Phase Assessments with Measures of Compliance Yield Accurate Dim Light Melatonin Onsets | Q28394275 |
| | Human tau in an ultradian light-dark cycle | Q28396732 |
| | Sex difference in the near-24-hour intrinsic period of the human circadian timing system | Q30427868 |
| | Aberrant light directly impairs mood and learning through melanopsin-expressing neurons | Q30532692 |
| | Melatonin administration can entrain the free-running circadian system of blind subjects | Q33884480 |
| | Entrainment of free-running circadian rhythms by melatonin in blind people | Q33921061 |
| | Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period | Q33959708 |
| | Capturing the circadian rhythms of free-running blind people with 0.5 mg melatonin | Q34099617 |
| | Comparisons of the variability of three markers of the human circadian pacemaker | Q34127753 |
| | Melatonin for the prevention and treatment of jet lag. | Q34134405 |
| | Influence of Melatonin Treatment on Human Circadian Rhythmicity before and after a Simulated 9-Hr Time Shift | Q48914275 |
| | The dim light melatonin onset as a marker for circadian phase position | Q48948299 |
| | Free-running activity rhythms in the rat: entrainment by melatonin | Q56485533 |
| | Melatonin phase advances circadian rhythm | Q60644598 |
| | Correlation between urinary cortisol and 6-sulphatoxymelatonin rhythms in field studies of blind subjects | Q61055162 |
| | Effects of a four-day nocturnal melatonin treatment on the 24 h plasma melatonin, cortisol and prolactin profiles in humans | Q67986554 |
| | Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol | Q70112069 |
| | Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature | Q73316999 |
| | Relationship between melatonin rhythms and visual loss in the blind | Q73853130 |
| | The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light | Q74287351 |
| | Nonphotic entrainment of the human circadian pacemaker | Q74518637 |
| | Impact of melatonin on driving performance | Q77410333 |
| | Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder | Q95587718 |
| | Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. | Q34238369 |
| | Different types of melatonin circadian secretory rhythms in some blind subjects | Q34271484 |
| | The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. | Q34272772 |
| | Molecular components of the Mammalian circadian clock | Q34340587 |
| | Circadian sleep regulation in the absence of light perception: chronic non-24-hour circadian rhythm sleep disorder in a blind man with a regular 24-hour sleep-wake schedule | Q34351923 |
| | Blind man living in normal society has circadian rhythms of 24.9 hours | Q34421511 |
| | Light as a central modulator of circadian rhythms, sleep and affect. | Q34424070 |
| | Circadian rhythm abnormalities in totally blind people: incidence and clinical significance | Q34454699 |
| | Prevalence of sleep/wake disorders in persons with blindness | Q34504255 |
| | Disruption of circadian clocks has ramifications for metabolism, brain, and behavior | Q34534170 |
| | Melatonin receptors: role on sleep and circadian rhythm regulation | Q34716949 |
| | Measuring melatonin in humans. | Q34762973 |
| | Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. | Q34894399 |
| | Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular S | Q36090692 |
| | Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans | Q36867614 |
| | Combination of light and melatonin time cues for phase advancing the human circadian clock | Q37219829 |
| | Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention | Q37282463 |
| | Melatonin, sleep disturbance and cancer risk | Q37354527 |
| | Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. | Q37665036 |
| | Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders | Q38175667 |
| | Tasimelteon: first global approval | Q38194529 |
| | Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals | Q38785024 |
| | Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials | Q40952954 |
| | Rest-Activity Cycle and Melatonin Rhythm in Blind Free-Runners Have Similar Periods | Q42874665 |
| | Melatonin treatment for eastward and westward travel preparation | Q43219782 |
| | A single dose of melatonin prevents the phase delay associated with a delayed weekend sleep pattern | Q43588430 |
| | Sleep logs of young adults with self-selected sleep times predict the dim light melatonin onset. | Q44104912 |
| | Sleep/wake cycles in the dark: sleep recorded by polysomnography in 26 totally blind subjects compared to controls | Q44154819 |
| | Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones | Q44582508 |
| | Eventual entrainment of the human circadian pacemaker by melatonin is independent of the circadian phase of treatment initiation: clinical implications | Q44765058 |
| | Evening melatonin and bright light administration induce additive phase shifts in dim light melatonin onset | Q44792187 |
| | Relative coordination to unknown "weak zeitgebers" in free-running blind individuals | Q46440468 |
| | Melatonin entrains free-running blind people according to a physiological dose-response curve | Q46879877 |
| | Phase advance with separate and combined melatonin and light treatment | Q48332227 |
| | The endogenous melatonin profile as a marker for circadian phase position | Q48748537 |
| | Sleep and activity rhythms are related to circadian phase in the blind. | Q48748816 |
| | Delayed sleep phase syndrome: A placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset | Q48792675 |
| | Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans | Q48808030 |
| | Melatonin Administration to Blind People: Phase Advances and Entrainment | Q48914251 |
| P433 | issue | 6 | |
| P921 | main subject | sleep-wake disorder | Q54972453 |
| P304 | page(s) | 637-650 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind | |
| P478 | volume | 77 | |